laparoscopic heller myotomy
Recently Published Documents


TOTAL DOCUMENTS

324
(FIVE YEARS 80)

H-INDEX

40
(FIVE YEARS 3)

2022 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Aditya Kumar ◽  
Samarendra N. Tripathi ◽  
Sonali Mittal ◽  
Joyner Abraham ◽  
Govind K. Makharia ◽  
...  

Author(s):  
Abdullah AL Jabri ◽  
Jessica Liu ◽  
Julie Takata ◽  
David R. Urbach

2021 ◽  
Vol 10 (23) ◽  
pp. 5565
Author(s):  
Amir Mari ◽  
Wisam Sbeit ◽  
Wisam Abboud ◽  
Halim Awadie ◽  
Tawfik Khoury

Achalasia is not uncommonly diagnosed in elderly patients and its incidence and prevalence are growing in this population. However, a scarcity of studies has assessed the typical pathophysiological and clinical features of the disease as well as the effectiveness and safety of the various therapeutic options in elderly populations. Botulinum toxin injection has been used for achalasia treatment since 1994 and is traditionally considered the preferred treatment for fragile elder patients. However, recently more evidence has become available regarding the safety and effectiveness of pneumatic balloon dilation (BD), laparoscopic Heller myotomy (LHM) and per-oral endoscopic myotomy (POEM) in elderly patients with achalasia. In the current review we present the current literature on this topic with a focus on the clinical presentation of achalasia in the elderly and manometric features thereof, as well as summarize the effectiveness and safety of the various therapeutic options. Furthermore, we propose a practical management algorithm as a means to guide the treatment of future cases. We recommend that a conservative/BTI approach should be adopted in the fragile unfit patient. In the elderly fit patient, the treatment decision should be based on the achalasia type, patient preference and the available expertise, similar to the approach adopted for the non-elderly population.


2021 ◽  
Vol 10 (16) ◽  
pp. 3607
Author(s):  
Amir Mari ◽  
Fadi Abu Baker ◽  
Rinaldo Pellicano ◽  
Tawfik Khoury

Achalasia is a rare neurodegenerative disorder causing dysphagia and is characterized by abnormal esophageal motor function as well as the loss of lower esophageal sphincter (LES) relaxation. The assessment and management of achalasia has significantly progressed in recent years due to the advances in high-resolution manometry (HRM) technology along with the improvements and innovations of therapeutic endoscopy procedures. The recent evolution of HRM technology with the inclusion of an adjunctive test, fluoroscopy, and EndoFLIP has enabled more precise diagnoses of achalasia to be made and the subgrouping into therapeutically meaningful subtypes. Current management possibilities include endoscopic treatments such as Botulinum toxin injected to the LES and pneumatic balloon dilation. Surgical treatment includes laparoscopic Heller myotomy and esophagectomy. Furthermore, in recent years, per oral endoscopic myotomy (POEM) has established itself as a principal endoscopic therapeutic alternative to the traditional laparoscopic Heller myotomy. The latest randomized trials report that POEM, pneumatic balloon dilatation, and laparoscopic Heller’s myotomy have comparable effectiveness and complications rates. The aim of the current review is to provide a practical clinical approach to dysphagia and to shed light on the most recent improvements in diagnostics and treatment of achalasia over the last two years.


Sign in / Sign up

Export Citation Format

Share Document